Syneron Candela (NASDAQ: ELOS) Investor...

Injecting energy into the lives of our patients

November 2015

Syneron Candela (NASDAQ: ELOS)

Investor Presentation

Safe Harbor For Forward Looking StatementsAny statements contained in this presentation regarding future expectations, beliefs, goals, plans or

prospects constitute forward-looking statements within the meaning of the Private Securities

Litigation Reform Act of 1995. Further, any statements that are not statements of historical fact

(including statements containing "believes," "anticipates," "plans," "expects," "may," "will," "would,"

"intends," "estimates" and similar expressions) should also be considered to be forward-looking

statements. There are a number of important risks and factors that could cause actual results or

events to differ materially from those indicated by forward-looking statements in this presentation,

including the risks set forth in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and

the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to

time. If one or more of these risks or factors materialize, or if any underlying assumptions prove

incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially

from any future results, performance or achievements expressed or implied by the forward-looking

statements in this presentation.

Non-GAAP Financial Measures

The following presentation includes certain "non-GAAP financial measures" as defined in

Regulation G under the Securities Exchange Act of 1934. A schedule is included in the company’s

Q2 2015 press release, which reconciles our results as reported under General Accepted

Accounting Principles and the non-GAAP financial measures included in the following presentation.

2

Syneron Candela at a Glance

• Strongest global brand name in the physician and professional

aesthetic technology market

• Clear technology innovator with the widest range of patented

technologies

• Diverse product portfolio and robust product pipeline

• Vast worldwide presence in sales, distribution, service network

and installed based

• Three technology solutions generating double digit growth in

underpenetrated markets

A global leader in medical aesthetic devices

1 Based on US publicly traded companies listed here (CYNO, CUTR, ZLTQ) for 3Q15; Professional Aesthetic Device Sector

2 Trailing twelve month revenue

³ September 30, 2015 Balance Sheet

28% Worldwide

Market Share¹

~$273M

Revenue²~$80M in Cash³;

No Debt

Drivers of Aesthetic Market Growth

• Increased global awareness, growing acceptance of cosmetic procedures

• Improved safety and efficacy and broader offerings of non-invasive procedures

• Growing middle class in high growth markets (China, and other APAC countries)

• Longer life expectancy - high demand from wealthy and middle class baby boomers

• Social media / celebrity culture – high demand from younger patients

Source: The American Society for Aesthetic Plastic Surgery 2015

Non-invasive procedures account for 83% and majority of growth

Source: Medical Insight, Inc.

¹ Includes Emerging Products

² Includes Skin Tightening

$1,366

$1,018

$1,521

$1,639

$998

Energy baseddevices¹

Body Shaping² &Liposuction

Neurotoxins Fillers PhysicianDispensed Topicals

2015 WW Sales of Aesthetic Products ($M)

The Global Aesthetic market (CAGR 2014 to 2019)

Total 2015 market size $6.6B with a

CAGR (2014-2019) of 12%

(9.2%)

(15%)

(8.8%)

(10.9%)

(8.4%)

▲

★▲

Syneron-Candela Corporate HQ (Yokneam, Israel)

Syneron-Candela NA HQ (Wayland, MA)

Direct International Sales (US, Canada, Australia, France, Germany, Italy, Japan,

Portugal, Spain, UK, China, Hong Kong, Israel)

Unmatched Global Footprint & Distribution

Vast WW presence in sales, distribution, service network and installed based

Strong brand name in all categories of non-invasive energy devices

Global infrastructure provides agility and flexibility

Rapidly deploying resources to high growth market

Channel to market capability in close to 100 countries

30,000 active customers

Body Shaping VascularFacial Treatments

Hair Removal Platform SystemsTattoos & Pigmentation

Non-Invasive

Fat Destruction

Laser Assisted

Liposuction

Body

Contouring

Rejuvenation

and Tightening

CO2

Resurfacing

Tightening and

Volumizing

Varicose

Veins

Vascular

Lesions

Diode Hair

Removal

IPL Hair

Removal

Gold Standard

Hair Removal

Solid State Multi

Application System

Tattoos and

Pigmentation

Skin

WighteningPicosecond

Technology

Diode/IPL Multi

Application System

Diverse Product Portfolio Across a Wide Range of In-Demand Applications

Facial Treatments

Hair Removal Tattoo/Pigment Removal

Body Shaping

Syneron Candela Strength in Numbers

5,000Systems installed worldwide

7,000systems installed worldwide



Vast Reach into Medical Aesthetic Practices

Drivers of Profitable Growth

• UltraShape™ and VelaShape™ Franchise in the fast growing Body

Shaping market segment

• PicoWay™ Breakthrough technology for Tattoo Removal, Pigmentation and

skin rejuvenation

• Profound™ Minimally invasive treatment of skin laxity, loss of volume and

submental fat lipolysis

Building Customer Centric and Consumer Centric Franchises in

Leading Categories of the Market

Superior Technology to Address the

Fat Destruction and Body Shaping Market

36

Targeting

connective tissueTargeting and

destroying fat

Holistic Approach to Body Shaping Treatments: Fat Cell Destruction, Skin Tightening and Cellulite

Potential Market for Body Shaping Procedures

154.7M Americans over the age of 20 are overweight or obese(1)

Target

Population

33.5%

Obese

32.6%

Overweight

33.8%

Normal or Underweight

Total Potential US Patient Market Approximately 100M Patients

9

Total Addressable Market in the US: 19.5M Patients³

1 2013 American Heart Association, Inc.

² Syneron proprietary consumer research, 2012³ 2013 Census estimates the US population 20 years and older to be 233M; and that 34.9% of the adult population has personal income of $35,000 or above

In a survey of 1,045 women in NA 56% indicated interest in non-invasive fat destruction procedures²

Market Learnings

• More than half of the women (56%) are interested in non-invasive fat destruction

• A pain free procedure is the #1 consideration for patients

• Almost three quarters (72%) of the women are unhappy with their abdomen and

want to remove fat from their stomach

• Almost half of the doctors (44%) are looking to buy non-invasive body shaping

equipment

14

Syneron is ideally positioned to serve these patient and doctor market needs

What do women look for in a non-invasive fat destruction treatment?

² Brown SA, Greenbaum L, Shtukmaster S, Zadok Y, Ben-Ezra S, Kushkuley L. Characterization of nonthermal focused ultrasound for noninvasive

selective fat cell disruption (lysis): technical and preclinical assessment. Plast Reconstr Surg. 2009 Jul;124(1):92-101

Superior Technology for Non Invasive Fat Destruction

Immediate Fat Cell Destruction!

17

Highly Selective!Exceptional Efficacy!

¹ Leal H. et al, Procedures in Cosmetic Dermatology (book); Focused Ultrasound for Fat Reduction: Ultralipotripsy. pp 107-121 (2010)

1Published in peer-reviewed journal 2Presented in scientific conference 3Data on file

13 published clinical studies with more than 900 subjects treated!

InvestigatorPublication

Year

Patient

Population

Avg. Circumference

ReductionResults

Teitelbaum S. et al1 US, UK, Japan 2007 164 2.0 cm (1 Tx) 82% > 0.5 cm circumference reduction

Leal H.2,3 Monterrey, Mexico 2009 24 3.0-3.4 cm (1 combo Tx)96% > 1.5 cm circumference reduction

100% patient satisfaction

Moreno-Moraga J1 Madrid, Spain 2007 30 3.95 cm (3 tx) 100% measurable and visual improvement

Leal H.2,3 Monterrey, Mexico 2008 36 5.0 cm (3 tx)100% measureable reduction


Ad El D.2,3 Beilinson Med, Israel 2008 26 3.96 cm (3 tx) 90% > 2.0 cm circumference reduction

Mulholland S.2 Toronto, Canada 2008 21 3.48 cm (3 tx) 86% patient satisfaction

Inglefield C.2 London, UK 2007 1486.3 cm (3 tx)


de Almeida G.2 Sao Paulo, Brazil 2007 205.4 cm (3 tx) 100% measurable reduction


Benchetrit A.2 Montreal, Canada 2010 1094.5 cm (3 tx) 96% measurable reduction


Niwa A. 1 São Paulo, Brazil. 2010 120 4.95 cm (3 tx)92% measurable reduction

94% reported comfortable treatment

Ascher B.1 Paris, France 2010 25 3.58 cm (3 tx) 90% reported no pain

S.-L. Chang1,2 Taiwan 2013 32 3.91 cm (3 tx)21.4% and 25% reduction in fat thickness

measured by MRI

Weiss, Coleman, Kenkel, Ad-El3 US, Israel 2013 32 3.34cm (3 tx) 100% reported very low pain levels

Superior Technology for Non Invasive, Immediate Fat Destruction

Average circumference reduction ranges from 3.3 to 6.3 cm (one to three pant

size reduction)

Average response rate ranged from 83% to 100%

20

UltraShape® Three Treatment Results

Reduction -4.7 cm upper, -5.4 cm

lower abdomen Weight change -2.2Kg

Pre-Treatment 4 Weeks Post

Treatment

Upper/ Lower Abdomen

Courtesy of Dr. Arie Benchetrit, Montreal, Quebec

Reduction -5 cmWeight change -2.2Kg

Pre-Treatment 4 Weeks Post Treatment

1521

UltraShape Non-Invasive Fat Destruction

Tracking & Guidance Camera

Tracking & Guidance Monitor

24

• Effective - 1 to 3 pant size

reductions

• Comfortable – No pain, Excellent

Safety Record

• Results seen as early as 2

weeks post treatment

• Flexible - Any shape and size of

fat pocket can be treated with the

VDF and U-Sculpt applicators

• Quick - enables enhanced

patient throughput – Less than 1

hour needed for full abdominal

treatment

UltraShape Treatments

High Margin Recurring Revenue Business Model

Revenues from Capital Equipment

System List Price $109,000*

• Consumables will be sold in the form of

Focal Treatment Zones (FTZ)

• Average abdominal treatment requires

10 FTZ’s

• Practice purchases FTZ’s based on

patient volumes

• Cost of FTZs represents 25%-33% of

treatment revenue charged by physician

Revenues from Consumables

FTZ List Price: $25

UltraShape Consumer Centric Business Model

25* List price as of November 2015

UltraShape® Exceptional Practice ROI

• New technology provides clinic differentiation – attracts new patients

• Cross selling opportunities with other offerings – attracts new patients

• Ongoing marketing and clinical support for practice

• Computer guided treatment

- Easy to learn & use

- High staff acceptance

10 new patients per month

(20 treatments per month) =

$220,000 - $250,000 in annual revenue

26

Ultrashape - AbdomenCompetitor - Abdomen

1

2 3

Same Treatment Size Comparison Per CompanyTreatment Area: Abdomen

• Treatment size: 240 cm2

• Treatment time: 180 mins

• Consumable cost: $525

• Treatment size: 300cm2


• Consumable cost: $250



• Consumable cost: $1,050

• # of Treatments: 2



• Consumable Cost: $750

• # of Treatments: 3

Single Treatment Single Treatment

Treatment Series Treatment Series

19

Body Portfolio Unique C5

Value Proposition

CoverageOver 50% more body area treated per hour

than competitors

CustomizationTailored to the contours of the patient’s body

CostBest ROI in body contouring

Combination TherapyUltraShape VelaShape for fat destruction and

tone & texture

ComfortMechanical effect, not thermal, for complete

patient comfort

UltraShape®: A Game Changer for Syneron Candela

2015 year-to-date U.S.

• 136 systems sold

• FTZ sales ~25% of total UltraShape revenue in Q3 2015

• Average of 2.5-3 treatments per week for established practices (equaling 130-

150 annual treatments per system)

• Continued ramp up and hiring of industry leading sales reps

• Planned 2015 revenue: $16M - $17M

$65M-$100M in UltraShape revenues within 3 years

• Above 70% gross margin on UltraShape business

• 50% capital equipment and 50% recurrent revenues within 3 years

• Achieving a long term win-win partnership with our customers

• International re-launch in 2016, expanding recurring revenue business model

29

VelaShape III

• FDA cleared for the treatment of cellulite and circumferential reduction (abdomen

and thighs)

• Increased RF Power by a factor of 2.5 to 150W

• Single treatment with an average abdominal circumferential reduction of 2.5cm

and 100% patient responders

Cellulite, Skin Laxity, Circumferential Reduction

31

After

Treatment of Skin Laxity with VelaShape Technology

Photos: Regine Bousquet, MD

Before

32

Body Shaping as a Growth Driver - Leveraging Our Strengths

• Installed base of ~15,000 systems in NA: more than 2,000 units in

body shaping

• Superior technology platforms

• Ability to offer comprehensive body shaping solutions for all major

indications (Non-Invasive Fat Destruction, Skin Laxity, Cellulite,

Circumference)

• Cross selling opportunities with other devices

34

North America Body Division

Bifurcated Body Shaping Business Group (team of 55 reps by end of 2015)

Territory Managers For

Capital Sales

• Initial Focus on Installations

• Expansion of installed base

• Ensure healthy pipeline

Practice Development

Partners (PDP’s)

• Focus on educating practices

• Provide marketing support

• Drive utilization of Focal

Treatment Zones (FTZs)

• Targeting 2,000 VelaShape NA installed base and users of competitive systems

• Potential for bundling with VelaShape

35

PicoWay Breakthrough Technology for Tattoo Removal and

Treatment of Pigmented Lesions

36

• Treat widest range of tattoos & pigmented lesions

2 wavelengths + ultra-short 450 picosecond pulses

enable treatment of more patients than single

wavelength picosecond units

• Compared to other picosecond or Q-switched lasers

PicoWay’s ultra-short pulses optimizes the

photoacoustic pressure on the target better than any

device, shattering the ink with the least amount of heat

transferred into the skin

• Pulse-on-demand

Lower cost of ownership than other picosecond laser

systems which run continuously throughout the day

• Compact system

Fast and easy to use

• Upgradability

Additional applications and upgrades

PicoWay – Shortest Picosecond Pulse, Highest Peak Power

38

Dual wavelength picosecond laser to treat tattoos of all types and colors, and

pigmented lesions on any skin type

PicoWay – Shortest Picosecond Pulse, Highest Peak Power

• FDA Clearance in late Oct. 2014 for removal of tattoos of all

colors; April 2015 for pigmented lesions

• Investing in sales & marketing to support launch

• US potential market for tattoo removal procedures: $11.4B - $22.7B1

• Received CE Mark in July 2014 for removal of tattoos of all

colors and pigmented lesions

• Received Korean regulatory clearance in July 2015

• PicoWay Resolve™ dual wavelength fractional modality

international launch in October 2015

• $260K list price and 15% higher gross margin on top of current

gross margin levels

• Growth driver with $11.4M in revenue in 9M 2015; FY2015 to

exceed $14M

Candela global installed

base of ~1,400 dedicated

tattoo removal & pigmented

lesion lasers and >11,000

platforms that include

pigmented lesion indications

¹ 2013 Census; 21% of adults in America have at least one tattoo; The Harris Poll, 2012 Harris Interactive; 14%

of those with a tattoo regret their tattoo; The Harris Poll, 2012 Harris Interactive; Estimated average tattoo

removal procedure fee is $400; 4-8 treatments required

37

PicoWay Treatment Results

Tattoo Removal and Pigmented Lesion

39

Profound High End Facial Aesthetic Treatments

36

Clinically proven to create New Elastin, Collagen & Hyaluronic Acid

Solution for Most In-Demand Facial Concerns

* Syneron Candela proprietary online consumer survey 2015

Growing Demand for High-End Facial Treatments

Profound™ Facial Aesthetics Treatments

• Minimally invasive microneedle electrode array with unique real-time temperature

controlled RF

• Creates dermal volume, naturally, to answer a big challenge physicians doing

aesthetic treatments have: how to replace lost volume in aging skin

• One treatment. One hour. 100% response. 2.6 years younger skin

• Long lasting and Predicatible results due to complete control over temperature

endpoints and duration of treatment

Recurring revenue model ($350 disposable tip)

Dedicated U.S. sales force under the Aesthetics Division

Profound Results in a Single Treatment

*Alexiades et al “Randomized, blinded, 3-arm clinical trial assessing optimal temperature and duration

for treatment with minimally invasive fractional radiofrequency”. Dermatol Surg. 2015 May;41(5):623-

32.

Profound single 30 min treatment of lower face and submental area(*)

Before treatment 3 months post treatment

*Alexiades et al “Randomized, blinded, 3-arm clinical trial assessing optimal temperature and duration

for treatment with minimally invasive fractional radiofrequency”. Dermatol Surg. 2015 May;41(5):623-

32.

Profound single 30 min treatment of lower face and

submental area(*)

Before treatment 3 months post treatment

From Kythera Background material to FDA, February 2015

Kybela treatment: up to 50 injections/session, up to 6 sessions required, cost to

doctor ~$250/session

Kybela treatment: up to 50 injections/session, up to 6 sessions required, cost to

doctor ~$250/session

From Kythera Background material to FDA, February 2015

Kybella (Kythera fat melting injections) vs. Profound

for submental (turkey neck) treatment comparison

KyBella Profound

Number of treatment

sessions

4 to 6 1

Cost to doctor/session ~$250 $350

Total treatment cost to

doctor

$1,000-$1,500 $350

Treatment effect Fat melting Fat melting, skin

tightening, generation of

collagen, elastin and

Hyaluronic acid

Responder rate to

treatment

~60-70% Close to 100%

Value of Energy Based Treatments• Patients spend almost twice as much money on energy based procedures than

on injectable treatments

• More than twice as many energy based procedures are performed annually than injectable treatments

• Only 41% of physician spending is for energy devices while 59% is spent on injectables

41%

59%

2015 WW Manufacturer Revenues

Energy Based Devices Fillers & Toxins

37

17

$7.3 $4.0

Energy Based Devices Fillers & Toxins

2015 WW Procedure Volumes & Fees

Procedure Volumes (MM) Procedure Fees ($B)

Source: Medical Insight, Inc.

Product Focus To-Date 2016 Going Forward

Injectable Energy… A Strategic Shift from Capital Equipment to

Pay-Per-Treatment Business Models

Areas

Body Shaping &

Skin Tightening

Skin

Rejuvenation

$588M, 14%

Hair

Removal¹

$550M

Full Pipeline to Support Strategy

Vascular

Lesions Pigmentation

& Tattoo

Source: Medical Insight Inc.

HR Includes IPL hair removal estimated figures (internal estimates)

Segment size

Pip

eli

ne

Vaginal

Tx

Re

v S

ha

re

20% 18% 25%

FTZCartridge

15%

$957M, 15%$120M, 12%$83M, 11%

2015 Sales, CAGR

PPP

10-15%

Financial Highlights

59

60

61

62

63

Q3 14 Q3 15

Y/Y Revenues ($M)

Revenue Highlights for Q3 2015

• Constant currency revenue growth of 8%

– Revenue negatively impacted by $3.0 million due to changes in foreign currency

exchange rates

– Primarily devaluation of the Euro and Japanese Yen against the U.S. dollar

• Total revenue was $62.1 million, up 3% y/y

• Recurring revenue was $17.7 million, down (2%) y/y

47

Total RevenuesRevenue

($M)Reported Growth

Constant Currency Growth

North America 23.9 9% 10%

International 38.2 (1%) 7%

Total 62.1 3% 8%

NA Product 16.1 15% 15%

EMEA Product 10.7 (18%) (13%)

APAC Product 15.7 18% 28%

LATAM Product 1.9 13% 13%

Total Product Revenues

44.4 5% 10%

3% (8% cc)

Financial Highlights 5Q Trend (Non-GAAP)$ Thousands (except per margins)

48

(*) Y2014 year-over-year comparison to Y2013 is on a pro-forma basis, excluding Syneron Beauty from Y2013 results following its de-consolidation as of December 8, 2013

Q3 14 Q4 14 Q1 15 Q2 15 Q3 15 Y2013 Y2014

Revenues 60,257 74,062 63,399 73,507 62,074 232,129 255,750

YOY change, % 8.3% 23.7% 11.6% 13.8% 3.0% (3.8%) 10.2%

Cost Of Revenue 26,775 32,810 29,654 33,904 26,679 105,187 115,592

Gross Profit 33,482 41,252 33,746 39,603 35,395 126,943 140,158

GM % 55.6% 55.7% 53.2% 53.9% 57.0% 54.7% 54.8%

Total OPEX 30,858 36,050 32,631 36,663 34,136 115,170 127,283

OPEX % 51.2% 48.7% 51.5% 49.9% 55.0% 49.6% 49.8%

EBIT 2,624 5,202 1,115 2,940 1,259 11,773 12,875

Operating Margin % 4.4% 7.0% 1.8% 4.0% 2.0% 5.1% 5.0%

Financial Income (expenses), net (764) (316) (243) 409 - 221 (688)

Pre Tax Income 1,860 4,886 872 3,349 1,259 11,994 12,187

Taxes on Income (tax benefit) 920 1,696 262 900 330 (1,431) 4,243

Tax rate 49% 35% 30% 27% 26%

Net Income 940 3,190 610 2,449 929 13,525 7,944

Avg Shares 37,228 37,128 37,328 37,384 36,672 36,254 37,160

EPS ($) 0.03 0.09 0.02 0.07 0.03 0.37 0.21

Act Act Act

14.1 16.1

13.1 10.7

13.3 15.7

0.0

10.0

20.0

30.0

40.0

50.0

Q3-2014 Q3-2015

North America EMEA APAC LATAM

38.4 38.2

21.8 23.9

0.0

10.0

20.0

30.0

40.0

50.0

60.0

70.0

Q3-2014 Q3-2015

International North America

Q3 2015 HighlightsY/Y Revenues ($M)

60.362.13%

9%

(1%)

Product Revenue ($M)

42.1

44.4

18%

(18%)

15%

49

8% const curr

10% const curr

7% const curr

28% const curr

(13%) const curr

15% const curr

38.0%

62.0%

Revenue by Geography

North America International

28.0%

72.0%

Revenue Mix

Recurring Product

0.03

0.07

0.03

0.00

0.02

0.04

0.06

0.08

Q3-2014 Q2-2015 Q3-2015

EPS ($)

4.4% 4.0%

2.0%

0%

2%

4%

6%

Q3-2014 Q2-2015 Q3-2015

Operating Margin %

55.6%53.9%

57.0%

48%

52%

56%

60%

Q3-2014 Q2-2015 Q3-2015

Gross Margin %

58.9%

(cc)

Select Financial (Non-GAAP) Items as of Q3 2015*

• Gross margin of 57.0% vs. 55.6% in Q3

2014

• 1.9% negative impact from changes in

foreign currency exchange rates

• Constant currency GM of 58.9%

• Operating margin of 2.0% vs. 4.4% in Q3

2014

• Includes net negative impact of ~$1.1

million related to changes in foreign

currency exchange rates

• Constant currency OM of 3.7%

• EPS of $0.03 vs. $0.03 in Q3 2014

• Q3 2015 EPS would have been $0.06

excluding changes in foreign currency

exchange rates

50

0.06

(cc)

3.7%

(cc)

• Expecting to add $3-4M S&M in 2H15 vs

1H15

• Expecting OM 4.5% for the full year 2015,

or 5.5%-6% in constant currency for 2015

Select Balance Sheet Items as of September 30, 2015

• $79.5 million in cash and cash equivalents as of September 30, 2015

• Used $8.3 million in cash from operations in Q3 2015

• Reflects investments in inventory to support growth and increased working capital

related to the Company’s increasing volumes and S&M investment

• $20M share repurchase program:

• Q3 2015 - repurchased 463,004 shares at avg. price of $9.47 for $4.4 million

• Since inception (Dec 2014), repurchased 894,671 shares at an avg. price of $10.36

for $9.4 million

• Board of Directors approved acceleration of share repurchase program

• DSO of 74 vs. 78 days in Q3 2014

• Expecting to drive further improvements in DSO, which combined with more

normalized inventory levels and spending, will put Company back on track to

generate positive cash flow from operations

Investment Highlights

Growing aesthetic market for non-invasive procedures; Growing consumer

demand and awareness of energy based, non-invasive aesthetic procedures

Unique growth opportunities with UltraShape™, PicoWay™ and Profound™

Leader in technology innovation with a rich product pipeline

A global leader in aesthetic devices with 28% worldwide market share1

Platform aesthetic company with largest worldwide presence, in sales, distribution

and service network across almost 100 countries capable of addressing largest

and fastest growing segments of market

Changing business model from capital equipment sales to recurring revenue

sales of disposables and revenue sharing with the doctor

Financially strong with diversified revenue growth drivers and improving

margins~$273 million revenue2 (~30% recurring3); $80 million in cash4; No debt

1 – Based on US publicly traded companies listed here (SLTM, CYNO, CUTR, ZLTQ); Professional Aesthetic Device Sector

2 – Trailing twelve month revenue

3 – Based on 3Q 2015

4 – September 30, 2015 Balance Sheet

Injecting energy into the lives of our patients

November 2015

Syneron Candela (NASDAQ: ELOS) Investor...

Documents

Transcript of Syneron Candela (NASDAQ: ELOS) Investor...